Now an important update to our coverage of a new Alzheimer’s drug that drew so much controversy. Aducanumab was approved without one yes vote from the FDA advisory committee. In fact, several members quit over it. And critics say it […]
An update on our coverage of the Alzheimer’s drug Aduhelm. And a resident of San Francisco’s drug-riddled Tenderloin District talks about the nightmarish turn she says the neighborhood has taken with the City’s permission.
After Hours: Alzheimer’s Drug Update & San Francisco’s Open-Air Drug Market (Podcast) Read More »
The chief executive of the drug company that created one of the most controversial drugs in the history of FDA approval is resigning, according to reports. Michael Vounatsos presided over Biogen during a rocky time during which the company halted,
CEO of company that makes miracle Alzheimer’s-drug-gone-wrong resigns Read More »
Medicare will only pay for patients to take a controversial new Alzheimer’s drug if they are enrolled in an approved study. That policy decision from the federal government is the latest blow to aducanumab, being sold by Biogen under the
The biggest new hope for a blockbuster drug to cure Alzheimer’s has been mired in controversy ever since it went to market. Critics say it’s a sign of declining standards and conflicts of interest at the FDA. And now, the
FDA Adviser Dr. Caleb Alexander of John’s Hopkins talks about Aducanumab/Aduhelm: a groundbreaking Alzheimer’s treatment sent to market in one of the most controversial FDA approvals ever.
An Alzheimer’s drug brought to market in one of the most controversial FDA approval processes ever– is the subject of my cover story this week on Full Measure. Aducanumab, now sold as Aduhelm, was introduced last June at a cost
After originally defending her agency’s process, FDA acting commissioner Janet Woodcock has now requested a review of the FDA’s controversial approval of an Alzheimer’s drug. There has been widespread criticism of last month’s approval of aducanumab sold under the brand
(WATCH) FDA does an about-face; requests investigation of Alzheimer drug approval Read More »
